Clinical Trial Update: Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of Basiliximab to prevent graft-versus-host disease after nonmyeloablative allogeneic transplantation in blood cancers; the study completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Hodgkin Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndromes
• Myelogenous Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Basiliximab (basiliximab)

Snippet

Sponsor: Indiana University School of Medicine | Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2016-02-26